Phenyl isoxazole voltage-gated sodium channel blockers: Structure and activity relationship

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 13, 2011, Pages 3871-3876

  Macsari, Istvan ^a   Sandberg, Lars ^a   Besidski, Yevgeni ^a   Gravenfors, Ylva ^a   Ginman, Tobias ^a   Bylund, Johan ^a   Bueters, Tjerk ^a   Eriksson, Anders B ^a   Lund, Per Eric ^a   Venyike, Elisabet ^a   Arvidsson, Per I ^a,b,c  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Na V1.7 blocker; Neuropathic pain; Phenyl isoxazoles; Sodium channel blockers; Voltage gated channel

Indexed keywords

AMIDE; CARBAMIC ACID DERIVATIVE; PHENYL ISOXAZOLE CARBAMATE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CARBAMATES; HUMANS; INFUSION PUMPS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; MOLECULAR STRUCTURE; PAIN; RATS; SODIUM CHANNEL BLOCKERS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 79958764880     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.05.041     Document Type: Article

References (45)

1. Alzheimer's Association: 2010 Alzheimer's disease facts and figures http://www.alz.org/national/documents/report-alzfactsfigures 2010.pdf.
2. See for example: (a) Hung, L. W.; Ciccotosto, G. D.; Giannakis, E.; Tew, D. J.; Perez, K.; Masters, C. L.; Cappai, R.; Wade, J. D.; Barnham, K. J. J. Neurosci. 2008, 28, 11950;
3. (b) Moreno, H.; Yu, E.; Pigino, G.; Hernandez, A. I.; Kim, N.; Moreira, J. E.; Sugimori, M.; Llinas, R. R. PNAS 2009, 106, 5901.
4. Thinakara, G.; Koo, E. H. J. Biol. Chem. 2008, 283, 29615.
5. C-99 is the C-terminal fragment of APP, which is formed from APP by BACE1 mediated proteolysis.
6. (a) Li, H.; Wolfe, M. S.; Selkoe, D. J. Cell Struct. 2009, 17, 326;
7. (b) Osenkowski, P.; Li, H.; Ye, W.; Li, D.; Aeschbach, L.; Fraering, P. C.; Wolfe, M. S.; Selkoe, D. J.; Li, H. J. Mol. Biol. 2009, 385, 642.
8. See for example: (a) Selkoe, D. J.; Wolfe, M. S. Cell 2007, 131, 215;
9. (b) Wolfe, M. S. Curr. Top. Med. Chem. 2008, 8, 2;
10. (c) Steiner, H.; Fluhrer, R.; Haass, C. J. Biol. Chem. 2008, 283, 29627;
11. (d) Wolfe, M. S. Semin. Cell Dev. Biol. 2009, 20, 219.
12. For selected reviews, see: (a) Wu, W.-L.; Zhang, L. Drug Dev. Res. 2009, 70, 94;
13. (b) Olson, R. E.; Albright, C. F. Curr. Top. Med. Chem. 2008, 8, 17;
14. (c) Imbimbo, B. P. Drug Discovery Today 2008, 5, 169;
15. (d) Zettl, H.; Weggen, S.; Schneider, P.; Schneider, G. Trends Pharmacol. Sci. 2010, 31, 402.
16. For a recent review on secretase biology and modes of γ-secretase inhibition/modulation, see: De Strooper, B.; Vassar, R.; Golde, T. Nat. Rev. Neurol. 2010, 6, 99.
17. All GSMs lower Aβ42 selectively over Aβ40, however, some raise the levels of Aβ38 others Aβ37. The consequence of this difference is unknown.
18. For selected reviews on GSMs, see: (a) Peretto, I.; La Porta, E. Curr. Top. Med. Chem. 2008, 8, 38;
19. (b) Breher, D. Curr. Top. Med. Chem. 2008, 8, 34;
20. (c) Imbimbo, B. P. Curr. Top. Med. Chem. 2008, 8, 54;
21. (d) Tomita, T. Expert Rev. Neurother. 2009, 9, 661.
22. Flurizan is the COX-inactive (COX1&2) enantiomer of (S)-Flurbiprofen.
23. For a recent comprehensive review of the GSM chemical space, see: Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. J. Med. Chem. 2011, 54, 669.
24. (a) For patents in this area, see: (a) Hannam, J. C.; Hartmann, S.; M., Andrew; R., Mark P. WO2007110667.;
25. (b) Madin, A.; Ridgill, M. P.; Kulagowski, J. J. WO 2007116228.;
26. (c) Garcia, Y.; Hannam, J. C.; Harrison, T.; Hamblett, C. L.; Hubbs, J. L.; Kulagowski, J. J.; Madin, A.; Ridgill, M. P.; Seward, E. WO 2007125364.;
27. (d) Stanton, M. G.; Munoz, B.; Sloman, D. L.; Hubbs, J. L.; Hamblett, C. L. WO 2008030391.;
28. (e) Munoz, B.; Hubbs, J. L.; Hamblett, C. L.; Zhou, H.; Martinez, M. WO 2008085301.
29. For a key patent, see: Kimura, T.; Kawano, K.; Doi, E.; Kitazawa, N.; Shin, K.; Miyagawa, T.; Kaneko, T.; Ito, K.; Takaishi, M.; Sasaki, T.; Hagiwara, H. WO 2005115990.
30. (a) Blurton, P.; Fletcher, S.; Teall, M.; Harrison, T.; Munoz, B.; Rivkin, A.; Hamblett, C.; Siliphaivanh, P.; Otte, K. WO 2008099210.;
31. (b) Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Hamblett, C. L.; Garcia, Y.; Martinez, M.; Munoz, B. WO 2010019392.
32. (a) Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Kim, Y. R.; Li, C.; Rosenau, A.; Kattar, S. D.; Jung, J.; Shah, S.; Hughes, B. L.; Crispino, J. L.; Middleton, R. E.; Szewczak, A. A.; Munoz, B.; Shearman, M. S. Bioorg. Med. Chem. Lett. 2010, 20, 1269;
33. (b) Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Hamblett, C. L.; Garcia, Y.; Martinez, M.; Hubbs, J. L.; Reutershan, M. H.; Daniels, M. H.; Siliphaivanh, P.; Otte, K. M.; Li, C.; Rosenau, A.; Surdi, L. M.; Jung, J.; Hughes, B. L.; Crispino, J. L.; Nikov, G. N.; Middleton, R. E.; Moxham, C. M.; Szewczak, A. A.; Shah, S.; Moy, L. Y.; Kenific, C. M.; Tanga, F.; Cruz, J. C.; Andrade, P.; Angagaw, M. H.; Shomer, N. H.; Miller, T.; Munoz, B.; Shearman, M. S. Bioorg. Med. Chem. Lett. 2010, 20, 2279.
34. Fischer, C.; Shah, S.; Hughes, B. L.; Nikov, G. N.; Crispino, J. L.; Middleton, R. E.; Szewczak, A. A.; Munoz, B.; Shearman, M. S. Bioorg. Med. Chem. Lett. 2011, 21, 773.
35. Fischer, C.; Munoz, B.; Zultanski, S.; Methot, J.; Zhou, H.; Brown, W. C. WO2008156580.
36. Careful work-up and purification was necessary to remove the unwanted regioisomer. See Ref. 18 for detailed synthetic procedures.
37. Other analogues were prepared in a similar manner. For detailed synthetic procedures, see Ref. 18.
38. 50 measurements for Aβ40 and Aβ42 were determined using electrochemiluminescent detection of peptides secreted by SH-SY5Y cells stably overexpressing the β-APP C-terminal fragment SPA4CT. All compounds were tested at least twice in independent experiments. Consistent with the profile of γ-secretase modulators, total Aβ peptide levels were constant; selected GSMs were confirmed in a SELDI experiment confirming the appearance of shorter fragments while Aβ42 formation was suppressed. (a) Best, J. D.; Jay, M. T.; Otu, F.; Ma, J.; Nadin, A.; Ellis, S.; Lewis, H. D.; Pattison, C.; Reilly, M.; Harrison, T.; Shearman, M. S.; Williamson, T. L.; Atack, J. R. J. Pharmacol. Exp. Ther. 2005, 313, 902;
39. (b) Clarke, E. E.; Shearman, M. S. J. Neurosci. Methods 2000, 102, 61;
40. (c) Dyrks, T.; Dyrks, E.; Monning, U.; Urmoneit, B.; Turner, J.; Beyreuther, K. FEBS Lett. 1993, 335, 89.
41. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2001, 40, 2004.
42. Not all compounds were profiled in our Notch nuclear translocation assay. Most compounds maintain a significant window over Notch. Key compounds were profiled in the following assay: HeLa cells were made to co-express nonfunctional halves of luciferase, one fused to NotchΔE and the other to RBP-Jł. γ-Secretase mediated cleavage of NotchDE results in release of Notch intracellular domain (NICD)/N-terminal luciferase, which translocates to the nucleus and binds the RBP-Jj/C-terminal luciferase to form a functional luciferase enzyme. This split-luciferase complementation system is used to detect NICD levels by measuring total luminescence upon addition of luciferin to lysed cells. Paulmurugan, R.; Gambhir, S. S. Anal. Chem. 2005, 77, 1295.
43. For a description of the hERG radioligand displacement assay, see: Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. WO 200205860.
44. A modest PgP susceptibility (rat-mdr1a BA/AB = 7.2) might be partially responsible for the lower brain exposure of compound 47.
45. The reduction of Aβ42 in PK/PD experiments was generally greater than the reduction of Aβ40, consistent with in vitro findings.